Get the Stockscreener App
14.30
5.22%
0.71
After Hours:
13.77
-0.53
-3.71%
Beta Bionics Inc stock is traded at $14.30, with a volume of 232.25K.
It is up +5.22% in the last 24 hours and down -20.07% over the past month.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.
See More
Previous Close:
$13.59
Open:
$13.79
24h Volume:
232.25K
Relative Volume:
0.49
Market Cap:
$619.99M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+11.46%
1M Performance:
-20.07%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$13.50
$14.32
1-Week Range:
$12.26
$14.32
52-Week Range:
$8.89
$24.36
Beta Bionics Inc Stock (BBNX) Company Profile
Name
Beta Bionics Inc
Sector
Industry
Phone
949-427-7785
Address
11 HUGHES, IRVINE
Compare BBNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBNX
Beta Bionics Inc
|
14.30 | 556.26M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
124.42 | 229.71B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.78 | 154.35B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
387.32 | 149.60B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
89.70 | 114.97B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.56 | 45.92B | 5.54B | 4.18B | 623.10M | 7.00 |
Beta Bionics Inc Stock (BBNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Truist | Buy |
| Jun-12-25 | Initiated | Lake Street | Buy |
| May-30-25 | Initiated | Goldman | Neutral |
| May-30-25 | Initiated | Wolfe Research | Outperform |
| Feb-24-25 | Initiated | BofA Securities | Buy |
| Feb-24-25 | Initiated | Lake Street | Buy |
| Feb-24-25 | Initiated | Leerink Partners | Outperform |
| Feb-24-25 | Initiated | Piper Sandler | Overweight |
| Feb-24-25 | Initiated | Stifel | Buy |
| Feb-20-25 | Initiated | Ladenburg Thalmann | Neutral |
| Feb-20-25 | Initiated | Robert W. Baird | Neutral |
View All
Beta Bionics Inc Stock (BBNX) Latest News
Beta Bionics, Inc.’s Lock-Up Period Will Expire on July 29th (NASDAQ:BBNX) - Defense World
What analysts say about Beta Bionics Inc. stockOutstanding yields - Autocar Professional
What drives Beta Bionics Inc. stock priceExceptional stock performance - PrintWeekIndia
Is Sprinklr Inc. a good long term investmentConsistent triple returns - jammulinksnews.com
Editas Medicine Inc. Stock Analysis and ForecastExponential wealth increase - jammulinksnews.com
Beta Bionics Inc. Stock Analysis and ForecastFree Investment Case Studies - jammulinksnews.com
NIP Group Inc. Depositary Receipt Stock Analysis and ForecastFree Investment Portfolio Suggestions - Autocar Professional
Is Beta Bionics Inc. a good long term investmentFree Stock Selection - jammulinksnews.com
Investing in IT Sector Top Investment Strategy ToolsExplosive trading opportunities - jammulinksnews.com
SKF India Limited (SKFINDIA) Stock RalliesFree Trend-Following Techniques - jammulinksnews.com
Best Indian Stocks for Stable Returns Professional Trading PicksFree Predictions - jammulinksnews.com
Beta Bionics (BBNX) Drops 2.15% Despite Abbott Partnership - AInvest
Why Beta Bionics Inc. stock attracts strong analyst attentionFree Access to Community with 300% Return - Newser
How Beta Bionics Inc. stock performs during market volatilityFree Step-by-Step Investment Guide - Newser
What makes Beta Bionics Inc. stock price move sharplyLow Risk Scalping Alerts - Newser
Abbott, Beta Bionics Partner to Integrate Dual Glucose-Ketone Sensor with iLet Bionic Pancreas - MSN
Sonnet BioTherapeutics Drops 5% Intraday, Rebounds 14% After Hours Amid Delisting Concerns - Benzinga
Beta Bionics, Inc. to Release Q2 2025 Financial Results on July 29, 2025 - Nasdaq
Beta Bionics to Announce Second Quarter 2025 Financial Results on July 29, 2025 - GlobeNewswire
Beta Bionics, Inc. (NASDAQ:BBNX) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Pump manufacturers: Patches are the fix for low AID uptake - BioWorld MedTech
ADA takeaways: Diabetes tech firms preview new patch pumps, glucose sensors - MedTech Dive
BBNX Stock May Gain From Abbott Deal to Advance iLet Integration - Zacks Investment Research
Analysts expect Beta Bionics patch pump launch by 2027 - MassDevice
5 things to watch at the ADA’s Scientific Sessions - MedTech Dive
Beta Bionics Announces Agreement with Abbott to Integrate the iLet Bionic Pancreas with Abbott's Future Dual Glucose-Ketone Sensor - MarketScreener
Global Artificial Pancreas Devices Market is Gearing Up for Outstanding Expansion at a CAGR of ~16% by 2032 | DelveInsight - GlobeNewswire Inc.
Beta Bionics (NASDAQ:BBNX) Now Covered by Truist Financial - Defense World
Beta Bionics initiated with a Buy at Truist - TipRanks
Beta Bionics, Inc.: Strategic Growth and Market Penetration with iLet Infusion Pump - TipRanks
Beta Bionics stock initiated with Buy rating at Truist Securities By Investing.com - Investing.com South Africa
Beta Bionics stock initiated with Buy rating at Truist Securities - Investing.com
Lake Street Capital Initiates Coverage on Beta Bionics (NASDAQ:BBNX) - Defense World
Beta Bionics, Inc. (NASDAQ:BBNX) Receives $23.13 Average Price Target from Brokerages - Defense World
Beta Bionics Executives Unload Shares in Major Stock Sell-Off! - TipRanks
Beta Bionics CEO, CFO on how to take a company public - MedTech Dive
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges - Benzinga
Wolfe Research Initiates Coverage of Beta Bionics (BBNX) Stock with Outperform Rating - Insider Monkey
Beta Bionics (NASDAQ:BBNX) Now Covered by The Goldman Sachs Group - Defense World
Beta Bionics (NASDAQ:BBNX) Coverage Initiated by Analysts at Wolfe Research - Defense World
Goldman Sachs Initiates Coverage of Beta Bionics (BBNX) with Neutral Recommendation - Nasdaq
Goldman Sachs sets Beta Bionics stock at Neutral with $16 target - Investing.com Australia
Beta Bionics initiated with an Outperform at Wolfe Research - TipRanks
Beta Bionics Inc Stock (BBNX) Financials Data
There is no financial data for Beta Bionics Inc (BBNX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.15%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):